Tweet
Front Immunol. 2019; 10: 3044.
Published online 2020 Jan 9. doi: 10.3389/fimmu.2019.03044
PMCID: PMC6962345
PMID: 31993057
Editorial: Immune Profile After Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand?
Kelen Cristina Ribeiro Malmegrim, Antoine Toubert, et al
Autologous hematopoietic stem cell transplantation (AHSCT) induces long-term remission in autoimmune diseases (AD) without further use of immunosuppression (1, 2). Recently, randomized trials have proven greater efficacy of AHSCT when compared to conventional therapies for multiple and systemic sclerosis (3–6). However, despite the overall positive outcomes, subgroups of patients reactivate the AD after AHSCT due to reasons not yet completely understood, indicating that additional specific immunological interventions may still be required to improve or sustain therapeutic efficacy of AHSCT.
This Frontiers Research Topic, combines reviews, opinions, and original research from the most active researchers in the field of AHSCT for AD. Here, clinical outcomes and immune mechanisms of AHSCT, as well as insights for future studies are presented in the setting of different AD.
ARTICLE (FREE):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962345/
Published online 2020 Jan 9. doi: 10.3389/fimmu.2019.03044
PMCID: PMC6962345
PMID: 31993057
Editorial: Immune Profile After Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand?
Kelen Cristina Ribeiro Malmegrim, Antoine Toubert, et al
Autologous hematopoietic stem cell transplantation (AHSCT) induces long-term remission in autoimmune diseases (AD) without further use of immunosuppression (1, 2). Recently, randomized trials have proven greater efficacy of AHSCT when compared to conventional therapies for multiple and systemic sclerosis (3–6). However, despite the overall positive outcomes, subgroups of patients reactivate the AD after AHSCT due to reasons not yet completely understood, indicating that additional specific immunological interventions may still be required to improve or sustain therapeutic efficacy of AHSCT.
This Frontiers Research Topic, combines reviews, opinions, and original research from the most active researchers in the field of AHSCT for AD. Here, clinical outcomes and immune mechanisms of AHSCT, as well as insights for future studies are presented in the setting of different AD.
ARTICLE (FREE):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962345/